Evidence map›Paper›PMID 39494754›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Personalized CZA-ATM dosing against an XDR E. coli in liver transplant patients; the application of the in vitro hollow fiber system.

Zahra Sadouki, Emmanuel Q Wey, Satheesh Iype, David Nasralla, Jonathan Potts, Mike Spiro, Alan Williams, Timothy D McHugh, Frank Kloprogge

Abstract readCase Reports
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zahra SadoukiInstitute for Global Health, University College London, London, UK.
Emmanuel Q WeyCentre of Clinical Microbiology, University College London, London, UK.ORCID https://orcid.org/0000-0003-2985-9524
Satheesh IypeDepartment of HPB and Liver Transplant Surgery, Royal Free Hospital, London, UK.
David NasrallaDepartment of HPB and Liver Transplant Surgery, Royal Free Hospital, London, UK.
Jonathan PottsDepartment of Hepatology, Sheila Sherlock Liver Unit, Royal Free London, London, UK.
Mike SpiroDepartment of Surgical Biotechnology, University College London, London, UK.
Alan WilliamsDepartment of Infection Sciences, Health Services Laboratories, London, UK.
Timothy D McHughCentre of Clinical Microbiology, University College London, London, UK.
Frank KloproggeInstitute for Global Health, University College London, London, UK.ORCID https://orcid.org/0000-0001-7213-4559

Funding

Shionogi B.V.Sir Henry Dale Fellowship 220587/Z/20/ZUKRI Medical Research Council Skills Development Fellowship MR/P014534/1University College LondonWellcome Trust
6 · The paper itself

Abstract

backgroundA patient with an extensively drug-resistant (XDR) New Delhi metallo-β-lactamase (NDM) and oxacillinase (OXA-48) producing Escherichia coli (E. coli) infection was awaiting orthotopic liver transplant. There is no standardized antibiotic prophylaxis regimen; however, in line with the Infectious Diseases Society of America guidance, an antibiotic prophylactic regimen of ceftazidime-avibactam 2.5 g TDS with aztreonam 2 g three times a day (TDS) IV was proposed.

methodsThe hollow fiber system (HFS) was applied to inform the individualized pharmacodynamic outcome likelihood prior to prophylaxis.

resultsA 4-log reduction in CFU/mL in the first 10 h of the regimen exposure was observed; however, the killing dynamics were slow and six 8-hourly infusions were required to reduce bacterial cells to below the limit of quantification. Thus, the HFS supported the use of the regimen for infection clearance; however, it highlighted the need for several infusions. Standard local practice is to administer prophylaxis antibiotics at induction of orthotopic liver transplantation (OLT); however, the HFS provided data to rationalize earlier dosing. Therefore, the patient was dosed at 24 h prior to their OLT induction and subsequently discharged 8 days after surgery.

conclusionThe HFS provides a dynamic culture solution for informing individualized medicine by testing antibiotic combinations and exposures against the bacterial isolates cultured from the patient's infection. .

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisAzabicyclo CompoundsCeftazidimeEscherichia coliEscherichia coli InfectionsLiver TransplantationAztreonambeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialHumansMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug Combinationsaztreonamceftazidime‐avibactamEscherichia colihollow fiber infection modelpersonalized medicineXDR

Identifiers

PMID39494754
PMCPMC11827718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.